Can Men Combine GLP-1 Injections with Testosterone or ED Treatments?

The concurrent use of GLP-1 receptor agonists (GLP-1 RAs, including tirzepatide), testosterone replacement therapy (TRT), and standard erectile dysfunction (ED) treatments is increasingly common in men with obesity, metabolic syndrome, diabetes, and hypogonadism. Current evidence and guidelines support the safety and potential benefit of these combinations in appropriately selected patients, with several important clinical considerations.
​
​GLP-1 RAs and Sexual Function:
​
GLP-1 RAs, including tirzepatide, are established therapies for obesity and type 2 diabetes, with robust evidence for weight loss, improved glycemic control, and reduction in cardiometabolic risk.[1][2][3][4][5][6][7][8][9][10][11][12][13] Recent Mendelian randomization and preclinical studies suggest that GLP-1 RAs may reduce the risk of ED, likely mediated by improvements in obesity, glycemic control, hypertension, and cardiovascular disease.[14][15] Clinical data also indicate that GLP-1 RAs may improve erectile function and testosterone levels in men with metabolic hypogonadism, with liraglutide and tirzepatide both demonstrating positive effects on sexual and reproductive parameters in obese men.[16][17] Large pharmacovigilance analyses have not identified a strong signal for increased sexual dysfunction with GLP-1 RAs, and the overall risk appears low.[18]
​
​Testosterone Replacement Therapy (TRT):
​
TRT is indicated for men with symptomatic hypogonadism and confirmed low testosterone, and is associated with improvements in libido, sexual function, muscle mass, and bone density.[19][20][21] In men with obesity and metabolic hypogonadism, GLP-1 RAs may increase endogenous testosterone by reducing adiposity and improving metabolic health, but TRT remains the standard for men with persistent symptomatic hypogonadism.[16][17][20][21] The Endocrine Society and the American Diabetes Association recommend screening for hypogonadism in men with diabetes or obesity and ED, and initiating TRT when indicated.[20][21]
​
​ED Treatments (PDE5 Inhibitors):
​
Phosphodiesterase type 5 inhibitors (PDE5i) remain first-line therapy for ED, including in men with diabetes and/or hypogonadism.[22][23][20][24] In men with hypogonadism and ED, combination therapy with TRT and PDE5i may be considered, particularly in those who are suboptimal responders to PDE5i alone.[23][20][24] However, meta-analyses suggest that the incremental benefit of adding TRT to PDE5i is modest and most pronounced in men with unequivocally low testosterone.[19][20][24]
​
​Combining GLP-1 RAs, TRT, and ED Therapies:
​
- There are no known pharmacokinetic or pharmacodynamic interactions that preclude the combined use of GLP-1 RAs, TRT, and PDE5i.
​
- GLP-1 RAs may indirectly improve sexual function and testosterone levels by reducing weight and improving metabolic health, and can be safely combined with TRT and ED therapies in men with appropriate indications. [16][22][17][14][15][25][24]
​
- In men with obesity-related hypogonadism, GLP-1 RAs (including tirzepatide) may improve both metabolic and gonadal parameters, and can be used alongside TRT if hypogonadism persists after weight loss. [16][17][20][21]
​
- In men with diabetes or prediabetes, the American Diabetes Association recommends screening for and treating both hypogonadism and ED, with individualized therapy based on symptoms, testosterone levels, and response to treatment. [21]
​
- The addition of GLP-1 RAs to standard ED management (lifestyle, PDE5i, TRT) may provide further benefit in men with obesity, diabetes, or metabolic syndrome, and is supported by recent expert opinion and clinical data.[22][17][14][15][25][24]
​
​Clinical Considerations:
​
- Monitor for gastrointestinal side effects with GLP-1 RAs, and titrate doses slowly to improve tolerability. [9][10][11][13]
​
- Assess for contraindications to TRT (e.g., prostate cancer, uncontrolled heart failure) and PDE5i (e.g., nitrate therapy). [20][24]
​
- Counsel patients regarding the expected benefits and limitations of each therapy, and set realistic goals for sexual function, weight loss, and metabolic health. [19][16][22][17][23][20][14][15][25][24][21][18]
​
- Consider periodic reassessment of testosterone levels and sexual function, especially after significant weight loss or metabolic improvement with GLP-1 RAs.[16][17][20][21]
​
In summary, the combination of GLP-1 RAs (including tirzepatide), TRT, and ED therapies is evidence-based and safe in men with appropriate indications, and may provide additive benefits for sexual, metabolic, and overall health. Individualized assessment and ongoing monitoring are essential to optimize outcomes and minimize risks.
​
​